Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
Top Page
Stereotaxis
(NYSE MKT:STXS)
59Neutral
Positive Factors
Financial Health
Free cash flow was positive in the quarter, at $1.3M, with no debt on the balance sheet.
Product Launches and Approvals
Recent milestones that bode well for momentum in 4Q and 2025 include last month's approval of the Magbot catheter in China, which followed closely on the heels of the Genesis RMN approval in China.
Strategic Collaborations
STXS’s acceptance into the NVIDIA Connect program marks a pivotal milestone in its long-term innovation strategy, enabling future advanced AI integration to enhance robotic precision, automation, and decision support.
Negative Factors
Financial Performance
The 4Q operating loss was $7.6M, while the net loss was $7.5M.
Regulatory Challenges
STXS anticipates a regulatory submission for the HD mapping catheter could be completed in early 2025.
Stereotaxis (STXS) vs. S&P 500 (SPY)
Market Cap
$150.46M
Dividend YieldN/A
Average Volume (3M)664.47K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth0.55%
EPS Growth-8.47%
CountryUS
Employees139
SectorHealthcare
Sector Strength74
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.30
Shares Outstanding85,979,660
10 Day Avg. Volume498,009
30 Day Avg. Volume664,465
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.13
Price to Cash Flow (P/CF)32.60
P/FCF Ratio29.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.67Price Target Upside181.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Stereotaxis Business Overview & Revenue Model
Company DescriptionStereotaxis, Inc. (STXS) is a leading medical technology company specializing in the development and commercialization of advanced robotic systems for the treatment of cardiac arrhythmias. The company operates within the healthcare and medical devices sector, focusing on providing innovative solutions that enhance the precision and safety of minimally invasive surgery. Its core products include the Niobe Magnetic Navigation System and the Genesis RMN System, which facilitate remote-controlled, magnetic-guided catheter navigation, enabling electrophysiologists to perform complex cardiac procedures with improved accuracy and reduced risk.
How the Company Makes MoneyStereotaxis generates revenue primarily through the sale of its robotic navigation systems, related disposable interventional devices, and ongoing service contracts. A significant portion of its income is derived from the installation of its systems in hospitals and medical facilities, where it also earns revenue from the sale of consumables and accessories required for each procedure. The company also engages in partnerships with healthcare providers and institutions to expand its reach and enhance its product offerings. Service agreements, including maintenance and support for the installed systems, provide a recurring revenue stream, contributing to the company's financial stability.
Stereotaxis Financial Statement Overview
Summary
Stereotaxis demonstrates consistent revenue but struggles with profitability due to high operational costs, resulting in negative net income. The balance sheet shows balanced leverage with a debt-to-equity ratio of 0.99 but limited equity. Cash flow challenges persist, with negative free cash flow reflecting the need for improved cash management.Income Statement
Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.65
Positive
Balance Sheet
The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.60
Neutral
Cash Flow
Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.58
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 25.14M | 26.92M | 26.77M | 28.15M | 35.02M | 26.63M | Gross Profit |
| 14.12M | 14.59M | 14.86M | 18.47M | 23.23M | 18.97M | EBIT |
| -22.42M | -24.74M | -21.84M | -18.78M | -12.89M | -6.71M | EBITDA |
| -21.52M | -24.74M | -21.24M | -18.35M | -12.78M | -6.59M | Net Income Common Stockholders |
| -21.57M | -25.35M | -20.71M | -19.15M | -8.44M | -6.45M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 9.04M | 12.22M | 19.82M | 28.43M | 38.74M | 43.94M | Total Assets |
| 22.44M | 46.72M | 41.91M | 53.41M | 60.98M | 55.46M | Total Debt |
| 5.59M | 6.01M | 5.49M | 5.86M | 6.11M | 4.45M | Net Debt |
| -3.45M | -6.21M | -14.33M | -2.73M | -32.63M | -39.49M | Total Liabilities |
| 17.11M | 35.29M | 19.99M | 21.48M | 21.56M | 15.23M | Stockholders Equity |
| 5.33M | 6.08M | 21.92M | 31.93M | 39.42M | 40.23M |
| Cash Flow | Free Cash Flow | ||||
| -12.23M | -8.53M | -9.51M | -10.79M | -4.34M | -3.58M | Operating Cash Flow |
| -12.20M | -8.50M | -9.14M | -8.41M | -2.95M | -3.51M | Investing Cash Flow |
| 76.00K | 74.00K | 19.77M | -22.09M | -1.40M | -70.90K | Financing Cash Flow |
| 164.00K | 297.00K | 81.00K | 220.00K | 547.41K | 17.34M |
Stereotaxis Technical Analysis
Negative
1.66
Price Trends
2.01
Negative
2.12
Negative
2.05
Negative
Market Momentum
-0.08
Positive
38.18
Neutral
5.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 1.66 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 2.01, and below the 200-day MA of 2.05, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.18 is Neutral, neither overbought nor oversold. The STOCH value of 5.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 58 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $31.79B | 25.57 | 25.65% | 0.96% | 9.38% | 40.38% | |
77 Outperform | $187.36B | 76.33 | 15.62% | ― | 17.24% | 27.76% | |
76 Outperform | $18.59B | 45.73 | 43.03% | ― | 22.07% | 101.95% | |
75 Outperform | $11.88B | 99.79 | 2.52% | ― | 60.62% | -35.88% | |
59 Neutral | $150.46M | ― | -144.19% | ― | 0.55% | -8.47% | |
51 Neutral | $782.79M | 55.81 | -5.16% | ― | -2.64% | -193.31% | |
48 Neutral | $6.36B | 1.28 | -45.04% | 2.64% | 19.24% | 1.69% |
* Healthcare Sector Average
Performance Comparison
STXS
Stereotaxis
1.66
-1.05
-38.75%
PODD
Insulet
253.99
78.77
44.95%
ISRG
Intuitive Surgical
489.52
104.72
27.21%
RMD
Resmed
210.55
26.36
14.31%
STAA
Staar Surgical
16.79
-33.00
-66.28%
GMED
Globus Medical
70.98
19.31
37.37%
Stereotaxis Earnings Call Summary
Earnings Call Date: Mar 3, 2025 | % Change Since: -19.42% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Neutral
Stereotaxis demonstrated strong revenue growth and made significant progress with FDA submissions and strategic acquisitions, which are expected to drive future growth. However, system revenue showed a slight decline, and recurring revenue faced challenges due to external dependencies. The company also reported a higher operating loss and commercial uncertainties in China. Overall, the call presents a balanced picture with potential for future growth tempered by current financial and market challenges.Highlights
Significant Revenue Growth
Fourth quarter revenue increased by 39% year-over-year, from $4.6 million to $6.3 million.
FDA Submissions for Key Innovations
Stereotaxis submitted FDA approvals for MAGIC Sweep and EMAGIN 5F catheters, enhancing their product offerings in EP and vascular procedures.
Strategic Acquisition Impact
The acquisition of APT has expanded catheter development and manufacturing capabilities, contributing positively to recurring revenue.
Product Launches in Europe and US
GenesisX robot received CE Mark in Europe. First firm order for GenesisX in Europe, with expected installation in the summer.
Positive Cash Flow
Stereotaxis reported a positive free cash flow of $1.3 million for the fourth quarter.
Lowlights
System Revenue Decline
Full year system revenue was slightly down from $8.7 million in 2023 to $8.6 million in 2024.
Recurring Revenue Challenges
Recurring revenue was impacted by catheter shortages from Johnson & Johnson, affecting overall financial performance.
Operating Loss
The company reported an adjusted operating loss of $12.8 million for the full year 2024, an increase from $11.3 million the previous year.
Commercial Uncertainties in China
Despite regulatory approval, commercial adoption in China faces challenges due to the macroeconomic environment and anti-corruption campaigns.
Company Guidance
During the Stereotaxis Fourth Quarter and Full Year 2024 Earnings Conference Call, CEO David Fischel provided detailed guidance on the company's strategic transformation. He outlined four key pillars: making the GenesisX robot widely available, expanding catheter and integration ecosystems in the EP ablation market, developing new interventional devices, and establishing connectivity and AI capabilities in cath labs. Fischel announced significant milestones, including the CE Mark approval for GenesisX in Europe and anticipated regulatory approvals for the MAGIC ablation catheter and MAGIC Sweep high-density mapping catheter in the US and Europe by Q3 2025. The company expects MAGIC revenue to reach approximately $1 million per quarter in Europe by year's end. Additionally, the EMAGIN vascular catheter was submitted for FDA approval, with strategic value anticipated in expanding the robot's applications. Financially, Stereotaxis reported a 39% year-over-year increase in Q4 2024 revenue to $6.3 million and guided for flat system revenue with double-digit overall growth in 2025.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.